<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on November 18, 2026 at 11:38 am by All in One SEO v5.0.5.1 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://helixgatebiotechreview.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Helixgate</title>
		<link><![CDATA[https://helixgatebiotechreview.com]]></link>
		<description><![CDATA[Helixgate]]></description>
		<lastBuildDate><![CDATA[Wed, 18 Nov 2026 11:14:11 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://helixgatebiotechreview.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://www.biospace.com/business/summits-rejection-isomorphics-record-5b-raise-obesity-and-alzheimers-in-the-spotlight]]></guid>
			<link><![CDATA[https://www.biospace.com/business/summits-rejection-isomorphics-record-5b-raise-obesity-and-alzheimers-in-the-spotlight]]></link>
			<title>Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 11:14:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/marrow-therapeutics-debuts-with-173m-to-tackle-blood-disorders-in-vivo]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/marrow-therapeutics-debuts-with-173m-to-tackle-blood-disorders-in-vivo]]></link>
			<title>Marrow Therapeutics debuts with $173M to tackle blood disorders in vivo</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 09:24:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/lilly-pens-another-deal-inking-up-to-5-9b-oncology-pact-with-stipple]]></guid>
			<link><![CDATA[https://www.biospace.com/business/lilly-pens-another-deal-inking-up-to-5-9b-oncology-pact-with-stipple]]></link>
			<title>Lilly pens another deal, inking up to $5.9B oncology pact with Stipple</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 09:23:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/ctad-2026-aribios-alzheimers-candidate-slows-cognitive-decline-as-monotherapy]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/ctad-2026-aribios-alzheimers-candidate-slows-cognitive-decline-as-monotherapy]]></link>
			<title>CTAD 2026: AriBio’s Alzheimer’s candidate slows cognitive decline as monotherapy</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 09:23:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/isomorphic-labs-breaks-biotech-vc-fundraising-record-with-5b-series-c]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/isomorphic-labs-breaks-biotech-vc-fundraising-record-with-5b-series-c]]></link>
			<title>Isomorphic Labs breaks biotech VC fundraising record with $5B series C</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 09:23:55 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/fda/white-house-yanks-overton-nomination-hours-before-committee-vote]]></guid>
			<link><![CDATA[https://www.biospace.com/fda/white-house-yanks-overton-nomination-hours-before-committee-vote]]></link>
			<title>White House yanks Overton nomination hours before committee vote</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 09:23:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/5-acquisitions-that-forced-big-pharmas-to-co-parent]]></guid>
			<link><![CDATA[https://www.biospace.com/business/5-acquisitions-that-forced-big-pharmas-to-co-parent]]></link>
			<title>5 acquisitions that forced Big Pharmas to co-parent</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 09:23:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/newdrugs/perioperative-imfinzi-approved-us-novel-regimen-neoadjuvant-enfortumab-vedotin-patients-muscle-6932.html]]></guid>
			<link><![CDATA[https://www.drugs.com/newdrugs/perioperative-imfinzi-approved-us-novel-regimen-neoadjuvant-enfortumab-vedotin-patients-muscle-6932.html]]></link>
			<title>Perioperative Imfinzi Approved in the US in Novel Regimen with Neoadjuvant Enfortumab Vedotin for Patients with Muscle-Invasive Bladder Cancer</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 04:36:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/newdrugs/fda-approves-klygefa-gefurulimab-generalised-myasthenia-gravis-6933.html]]></guid>
			<link><![CDATA[https://www.drugs.com/newdrugs/fda-approves-klygefa-gefurulimab-generalised-myasthenia-gravis-6933.html]]></link>
			<title>FDA Approves Klygefa (gefurulimab) for the Treatment of Generalised Myasthenia Gravis</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 04:36:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/newdrugs/genentech-s-gazyva-becomes-first-fda-approved-primary-membranous-nephropathy-6934.html]]></guid>
			<link><![CDATA[https://www.drugs.com/newdrugs/genentech-s-gazyva-becomes-first-fda-approved-primary-membranous-nephropathy-6934.html]]></link>
			<title>Genentech’s Gazyva Becomes the First FDA-Approved Treatment for Primary Membranous Nephropathy</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 04:36:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/newdrugs/fda-approves-pebrilzo-pertuzumab-qcay-biosimilar-perjeta-6935.html]]></guid>
			<link><![CDATA[https://www.drugs.com/newdrugs/fda-approves-pebrilzo-pertuzumab-qcay-biosimilar-perjeta-6935.html]]></link>
			<title>FDA Approves Pebrilzo (pertuzumab-qcay), a Biosimilar to Perjeta</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 04:36:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/newdrugs/fda-approves-wilserdly-giredestrant-er-positive-esr1-mutated-advanced-breast-cancer-6938.html]]></guid>
			<link><![CDATA[https://www.drugs.com/newdrugs/fda-approves-wilserdly-giredestrant-er-positive-esr1-mutated-advanced-breast-cancer-6938.html]]></link>
			<title>FDA Approves Wilserdly (giredestrant) for ER-Positive, ESR1-Mutated Advanced Breast Cancer</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 04:36:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/newdrugs/u-s-fda-approves-igalmi-first-home-acute-agitation-associated-schizophrenia-schizoaffective-6936.html]]></guid>
			<link><![CDATA[https://www.drugs.com/newdrugs/u-s-fda-approves-igalmi-first-home-acute-agitation-associated-schizophrenia-schizoaffective-6936.html]]></link>
			<title>U.S. FDA Approves Igalmi as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 04:36:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/newdrugs/cytokinetics-announces-myqorzo-aficamten-expanded-include-data-phase-3-maple-hcm-6937.html]]></guid>
			<link><![CDATA[https://www.drugs.com/newdrugs/cytokinetics-announces-myqorzo-aficamten-expanded-include-data-phase-3-maple-hcm-6937.html]]></link>
			<title>Cytokinetics Announces Prescribing Information for Myqorzo (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 04:36:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/newdrugs/fda-grants-accelerated-approval-nelkarmi-neladalkib-previously-treated-advanced-alk-positive-non-6940.html]]></guid>
			<link><![CDATA[https://www.drugs.com/newdrugs/fda-grants-accelerated-approval-nelkarmi-neladalkib-previously-treated-advanced-alk-positive-non-6940.html]]></link>
			<title>FDA Grants Accelerated Approval to Nelkarmi (neladalkib) for Previously-Treated Advanced ALK-Positive Non-Small Cell Lung Cancer</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 04:36:03 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/newdrugs/novartis-cosentyx-becomes-first-only-fda-approved-anti-il-17-biologic-polymyalgia-rheumatica-6939.html]]></guid>
			<link><![CDATA[https://www.drugs.com/newdrugs/novartis-cosentyx-becomes-first-only-fda-approved-anti-il-17-biologic-polymyalgia-rheumatica-6939.html]]></link>
			<title>Novartis Cosentyx Becomes First and Only FDA-Approved Anti-IL-17 Biologic for People with Polymyalgia Rheumatica</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 04:36:03 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/17/sellas-blood-cancer-immunotherapy-succeeds-clinical-trial/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/17/sellas-blood-cancer-immunotherapy-succeeds-clinical-trial/?utm_campaign=rss]]></link>
			<title>STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 03:45:35 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/17/capsida-gene-therapy-trial-death-follow-up-investigation/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/17/capsida-gene-therapy-trial-death-follow-up-investigation/?utm_campaign=rss]]></link>
			<title>STAT+: After death in gene therapy trial for a brain disease, progress is reported</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 03:45:35 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/17/new-startup-developing-novel-sickle-cell-anemia-infusion-no-gene-therapy/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/17/new-startup-developing-novel-sickle-cell-anemia-infusion-no-gene-therapy/?utm_campaign=rss]]></link>
			<title>STAT+: With $173 million, new startup takes aim at sickle cell</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 03:45:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/convenience-kit-correction-cardinal-health-issues-correction-presource-packs-containing-bd-alaris]]></guid>
			<link><![CDATA[http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/convenience-kit-correction-cardinal-health-issues-correction-presource-packs-containing-bd-alaris]]></link>
			<title>Convenience Kit Correction: Cardinal Health Issues Correction for Presource Packs Containing BD Alaris Pump Infusion Sets</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 01:02:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.labiotech.eu/top-pharma-strategy/regeneron-pipeline-2027/]]></guid>
			<link><![CDATA[https://www.labiotech.eu/top-pharma-strategy/regeneron-pipeline-2027/]]></link>
			<title>Where is Regeneron headed after record third quarter? </title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 23:11:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/pharmalot/2026/11/17/roche-breast-cancer-pill-obesity-drugs-in-children/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/pharmalot/2026/11/17/roche-breast-cancer-pill-obesity-drugs-in-children/?utm_campaign=rss]]></link>
			<title>STAT+: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and more</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 22:39:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/17/biotech-news-flagship-opens-biotech-creation-uk-outpost/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/17/biotech-news-flagship-opens-biotech-creation-uk-outpost/?utm_campaign=rss]]></link>
			<title>STAT+: Flagship opens biotech-creation outpost in the U.K.</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 22:39:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/sellas-cancer-vaccine-slashes-death-risk-by-41-in-late-stage-aml-study]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/sellas-cancer-vaccine-slashes-death-risk-by-41-in-late-stage-aml-study]]></link>
			<title>Sellas’ cancer vaccine slashes death risk by 41% in late-stage AML study</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 21:17:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/fda/vertex-on-the-verge-of-iconic-evolution-as-key-kidney-disease-verdict-looms]]></guid>
			<link><![CDATA[https://www.biospace.com/fda/vertex-on-the-verge-of-iconic-evolution-as-key-kidney-disease-verdict-looms]]></link>
			<title>Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict looms</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 21:17:39 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/plasma-protein-panel-distinguishes-parkinsons-disease-from-healthy-controls-in-study/]]></guid>
			<link><![CDATA[https://bioengineer.org/plasma-protein-panel-distinguishes-parkinsons-disease-from-healthy-controls-in-study/]]></link>
			<title>Plasma Protein Panel Distinguishes Parkinson’s Disease From Healthy Controls in Study</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 20:49:55 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/moringa-leaf-silver-nanoparticles-inhibit-drug-resistant-hospital-pathogens-in-lab-tests/]]></guid>
			<link><![CDATA[https://bioengineer.org/moringa-leaf-silver-nanoparticles-inhibit-drug-resistant-hospital-pathogens-in-lab-tests/]]></link>
			<title>Moringa Leaf Silver Nanoparticles Inhibit Drug-Resistant Hospital Pathogens in Lab Tests</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 20:49:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/helus-shares-slide-psychedelic-readout-depression]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/helus-shares-slide-psychedelic-readout-depression]]></link>
			<title>Helus shares slide on psychedelic readout in depression</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 20:07:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/uk-sets-2029-timeline-end-palantirs-nhs-contract]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/uk-sets-2029-timeline-end-palantirs-nhs-contract]]></link>
			<title>UK sets 2029 timeline to end Palantir&#8217;s NHS contract</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 20:07:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/roche-joins-oral-serd-club-fda-clears-wilserdly]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/roche-joins-oral-serd-club-fda-clears-wilserdly]]></link>
			<title>Roche joins the oral SERD club as FDA clears Wilserdly</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 20:07:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/isomorphic-labs-raises-5bn-massive-third-round]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/isomorphic-labs-raises-5bn-massive-third-round]]></link>
			<title>Isomorphic Labs raises $5bn in massive third round</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 20:07:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/amylyx-pharmaceuticals-presents-results-phase-3-lucidity-clinical-trial-avexitide-post-bariatric-22687.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/amylyx-pharmaceuticals-presents-results-phase-3-lucidity-clinical-trial-avexitide-post-bariatric-22687.html]]></link>
			<title>Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 18:23:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/wegovy-resulted-bmi-reduction-10-more-almost-80-children-obesity-aged-6-under-12-compared-0-placebo-22686.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/wegovy-resulted-bmi-reduction-10-more-almost-80-children-obesity-aged-6-under-12-compared-0-placebo-22686.html]]></link>
			<title>Wegovy Resulted in a BMI Reduction of 10% or More in Almost 80% of Children with Obesity Aged 6 to Under 12, Compared to 0% with Placebo in STEP Young Trial, Published in The New England Journal of Medicine</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 18:23:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/novo-s-cagrisema-associated-25-mean-weight-loss-among-early-responders-post-hoc-analysis-redefine-1-22685.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/novo-s-cagrisema-associated-25-mean-weight-loss-among-early-responders-post-hoc-analysis-redefine-1-22685.html]]></link>
			<title>Novo&#8217;s CagriSema was Associated with 25% Mean Weight Loss Among Early Responders in a Post Hoc Analysis of REDEFINE 1</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 18:23:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/island-kinetics-inc-dba-covalence-laboratories-726379-07162026]]></guid>
			<link><![CDATA[http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/island-kinetics-inc-dba-covalence-laboratories-726379-07162026]]></link>
			<title>Island Kinetics, Inc. d.b.a. CoValence Laboratories &#8211; 726379 &#8211; 07/16/2026</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 17:01:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/biospace-layoff-tracker]]></guid>
			<link><![CDATA[https://www.biospace.com/biospace-layoff-tracker]]></link>
			<title>AstraZeneca, Calidi, Tempest make significant workforce cuts</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 15:44:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities]]></link>
			<title>Registered Outsourcing Facilities</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 15:33:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661602/sofinnova-partners-goes-bigger-with-725m-crossover-ii-fund?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661602/sofinnova-partners-goes-bigger-with-725m-crossover-ii-fund?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Sofinnova Partners goes bigger with €725M Crossover II fund</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 13:03:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661623/lexeo-plans-pivotal-gene-therapy-trial-aimed-at-accelerated-approval?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661623/lexeo-plans-pivotal-gene-therapy-trial-aimed-at-accelerated-approval?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Lexeo plans pivotal gene therapy trial aimed at accelerated approval</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 13:02:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661498/rare-disease-spotlight-attacking-the-same-bleeding-problem-from-four-directions?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661498/rare-disease-spotlight-attacking-the-same-bleeding-problem-from-four-directions?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Rare Disease Spotlight: Attacking the same bleeding problem from four directions</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 13:02:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661621/after-gene-therapy-setbacks-j-j-pays-2-2b-for-ollin-adds-retinal-disease-candidate?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661621/after-gene-therapy-setbacks-j-j-pays-2-2b-for-ollin-adds-retinal-disease-candidate?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>After gene therapy setbacks, J&amp;J  pays $2.2B for Ollin, adds retinal disease candidate</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 13:02:37 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661634/fda-holds-summit-to-survival-bar-in-ivonescimab-crl?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661634/fda-holds-summit-to-survival-bar-in-ivonescimab-crl?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>FDA holds Summit to survival bar in ivonescimab CRL</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 13:02:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files]]></link>
			<title>Drugs@FDA Data Files</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 12:42:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/genome-editing/single-cell-method-reveals-on-and-off-target-effects-of-cas9-edits-on-gene-expression/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/genome-editing/single-cell-method-reveals-on-and-off-target-effects-of-cas9-edits-on-gene-expression/]]></link>
			<title>Single-Cell Method Reveals On- and Off-Target Effects of Cas9 Edits on Gene Expression</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 09:34:03 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/toward-connected-laboratory-ecosystems/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/toward-connected-laboratory-ecosystems/]]></link>
			<title>Toward Connected Laboratory Ecosystems</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 09:33:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/translational-medicine/enhancer-targeted-crispr-turns-up-healthy-gene-copy-in-autism-organoid-model/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/translational-medicine/enhancer-targeted-crispr-turns-up-healthy-gene-copy-in-autism-organoid-model/]]></link>
			<title>Enhancer-Targeted CRISPR Turns Up Healthy Gene Copy in Autism Organoid Model</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 09:33:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/16/fda-approves-new-roche-breast-cancer-drug/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/16/fda-approves-new-roche-breast-cancer-drug/?utm_campaign=rss]]></link>
			<title>STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 05:39:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.pharmavoice.com/news/china-pharma-global-expansion-us-commercialization/874673/]]></guid>
			<link><![CDATA[https://www.pharmavoice.com/news/china-pharma-global-expansion-us-commercialization/874673/]]></link>
			<title>China’s pharma industry wants to go global. The US could get in its way.</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 04:41:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/sofinnova-crossover-fund-ii-european-investment/874656/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/sofinnova-crossover-fund-ii-european-investment/874656/]]></link>
			<title>One of Europe’s leading VCs banks a €725M ‘crossover’ fund</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 02:07:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://helixgatebiotechreview.com/]]></guid>
			<link><![CDATA[https://helixgatebiotechreview.com/]]></link>
			<title>Home</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 03:39:54 +0000]]></pubDate>
		</item>
				</channel>
</rss>
